Catalent makes major investment to expand inhalation capabilities in Research Triangle Park, NC
10 January 2013 | By Catalent Pharma Solutions
The investment will focus on expanding pMDI clinical and commercial supply capabilities...
List view / Grid view
News
New Abbott test available in Europe provides novel tool to aid doctors in evaluating potential heart attacks
An estimated 17 million people throughout the world die annually of cardiovascular diseases, specifically heart attacks or strokes.1 Time is a critical factor in diagnosing and treating people who may be having a potential heart attack. To aid physicians in detecting heart attacks sooner, Abbott announced today CE Marking (Conformité…
GSK and Theravance announce regulatory submission for ANORO™ (UMEC/VI) in Europe
9 January 2013 | By GlaxoSmithKline
GSK and Theravance announced the submission of a regulatory application...
B&W Tek, Inc announces New Director of Analytical Services and Support
9 January 2013 | By B&W Tek, Inc.
B&W Tek, Inc., announces Dr. Katherine Bakeev as the new Director of Analytical Services and Support...
Daiichi Sankyo and Amplimmune announce strategic alliance to develop AMP-110 therapy
8 January 2013 | By Daiichi Sankyo
Daiichi Sankyo & Amplimmune have entered into a broad strategic collaboration...
Sanofi provides an update on its research & development pipeline
8 January 2013 | By Sanofi
Sanofi will provide an update on its Research & Development (R&D) pipeline...
Abbott initiates clinical trial of Absorb™ in the United States
8 January 2013 | By Abbott
Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States...
Lonza to expand Antibody Drug Conjugate (ADC) manufacturing capacity to meet growing customer demand
Lonza today announced plans to invest CHF 14 million to expand Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland. Oncology therapeutics including ADCs represent one of the fastest growing segments of the pharma and biotech industry and the deployment of ADC targeted therapies has intensified in recent years.
FOSS NIR article: Discriminant Analysis of Raw Materials Using Near-Infrared Spectroscopy
8 January 2013 | By FOSS NIRSystems Inc
FOSS NIRSystems, Inc. announce that a new FOSS NIR article has been published...
Gilead provides update on Hepatitis C development programs
7 January 2013 | By Gilead Sciences
Gilead Sciences announced several updates regarding its late-stage pipeline candidates for the treatment of chronic HCV infection...
Positive top-line pivotal Phase III data results for empagliflozin
7 January 2013 | By Boehringer Ingelheim
Top-line results for four completed Phase III clinical trials...
Sirius Analytical and Paraytec enter into development and technology licensing agreement
7 January 2013 | By Sirius Analytical Instruments Ltd
“We are delighted to begin this strategic partnership with Paraytec..."
Pharmapack 2013: Gerresheimer custom-packs pharma products
7 January 2013 | By Gerresheimer
Gerresheimer is exhibiting at Pharmapack 2013, 13-14 February, stands 133 and 372...
Sanofi appoints Dr. Gary J. Nabel as Chairman of the SDSAC
7 January 2013 | By Sanofi
“I am delighted that Dr. Gary Nabel will continue to make this Council a vital part of our efforts..."
Lilly reassumes sole worldwide development and commercialization rights for novel basal insulin analog
7 January 2013 | By Boehringer Ingelheim
Announces it will begin remainder of pre-planned clinical trials for LY2605541...
